TNGX250117C5000
- 0.15
- 0.000.00%
Tango Therapeutics Newsroom
Tango Therapeutics Analyst Ratings
B.Riley Financial Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Cuts Target Price to $8
Guggenheim Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $8
H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $13
Promising Developments and Strategic Shifts at Tango Therapeutics: A Buy Rating With a $13 Price Target
Tango Therapeutics Is Maintained at Buy by Guggenheim
Tango Therapeutics Analyst Ratings
Barclays Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $13
Barclays Keeps Their Buy Rating on Tango Therapeutics (TNGX)
Wedbush Adjusts Tango Therapeutics Price Target to $9 From $13, Maintains Outperform Rating
Tango Therapeutics Analyst Ratings
H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $13
Piper Sandler Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $18
Leerink Partners Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $19
Tango Therapeutics: A Buy Rating on PRMT5 Inhibitor Prospects and Upcoming Clinical Data
Piper Sandler Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $18
Barclays Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $13
Barclays Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $13
HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $13 Price Target
Tango Therapeutics Analyst Ratings